Poseida Therapeutics Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
350
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$931M
Poseida Therapeutics General Information
Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Contact Information
Website
www.poseida.com(Operating Subsidiary)
Corporate Office
- 9390 Towne Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 9390 Towne Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Poseida Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 08-Jan-2025 | $931M | Completed | Generating Revenue | ||
| 10. PIPE | 07-Aug-2023 | Completed | Generating Revenue | |||
| 9. IPO | 10-Jul-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series D) | 24-Jun-2020 | Completed | Generating Revenue | |||
| 7. IPO | 04-Jan-2019 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 22-Apr-2019 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 03-Apr-2018 | Completed | Generating Revenue | |||
| 4. Grant | Completed | Generating Revenue | ||||
| 3. Grant | 26-Oct-2017 | $19.8M | $41.2M | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A1) | 02-Aug-2017 | $11.2M | $41.2M | Completed | Generating Revenue |
Poseida Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 3,370,263 | $0.000100 | $3.43 | $3.43 | 1x | $3.43 | 4.98% | |
| Series A | 9,696,798 | $0.000100 | $3.43 | $3.43 | 1x | $3.43 | 14.32% |
Poseida Therapeutics Comparisons
Industry
Financing
Details
Poseida Therapeutics Competitors (41)
One of Poseida Therapeutics’s 41 competitors is Vor Biopharma, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany |
Poseida Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Poseida Therapeutics Patents
Poseida Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231998-A1 | Methods of treating extramedullary disease with p-bmca-allo1 car-t cells | Pending | 01-May-2025 | ||
| WO-2026107078-A1 | Chimeric antigen receptor compositions and methods of use | Pending | 13-Nov-2024 | ||
| WO-2026107088-A1 | Dual car constructs and methods of use | Pending | 13-Nov-2024 | ||
| WO-2026107085-A1 | Methods of treating lupus with cd19-cd20 dual car-t cells | Pending | 13-Nov-2024 | ||
| WO-2026107075-A1 | Methods of treating multiple sclerosis with cd19-cd20 dual car-t cells | Pending | 13-Nov-2024 | A61K40/11 |
Poseida Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Poseida Therapeutics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Aisling Capital | Venture Capital | Minority | ||
| Astellas Pharma | Corporation | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority | ||
| California Institute for Regenerative Medicine | Government | Minority |
Poseida Therapeutics Acquisitions (1)
Poseida Therapeutics’s most recent deal was a Merger/Acquisition with Vindico Pharma for . The deal was made on 10-Oct-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vindico Pharma | 10-Oct-2016 | Merger/Acquisition | Drug Discovery |
Poseida Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 31, 2023
27.42 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Poseida Therapeutics FAQs
-
When was Poseida Therapeutics founded?
Poseida Therapeutics was founded in 2014.
-
Where is Poseida Therapeutics headquartered?
Poseida Therapeutics is headquartered in San Diego, CA.
-
What is the size of Poseida Therapeutics?
Poseida Therapeutics has 350 total employees.
-
What industry is Poseida Therapeutics in?
Poseida Therapeutics’s primary industry is Drug Discovery.
-
Is Poseida Therapeutics a private or public company?
Poseida Therapeutics is a Private company.
-
What is the current valuation of Poseida Therapeutics?
The current valuation of Poseida Therapeutics is .
-
What is Poseida Therapeutics’s current revenue?
The current revenue for Poseida Therapeutics is .
-
How much funding has Poseida Therapeutics raised over time?
Poseida Therapeutics has raised $573M.
-
Who are Poseida Therapeutics’s investors?
Adage Capital Management, Aisling Capital, Astellas Pharma, Boxer Capital, and California Institute for Regenerative Medicine are 5 of 16 investors who have invested in Poseida Therapeutics.
-
Who are Poseida Therapeutics’s competitors?
Vor Biopharma, Carisma Therapeutics, Fate Therapeutics, Adaptimmune Therapeutics, and TME Pharma are some of the 41 competitors of Poseida Therapeutics.
-
When was Poseida Therapeutics acquired?
Poseida Therapeutics was acquired on 08-Jan-2025.
-
Who acquired Poseida Therapeutics?
Poseida Therapeutics was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
